Immunotec has appointed two Heads of Business Development for North America: Mandy Boles and Maribeth Dodd. This dual-leadership model is moving toward a new strategic architecture that the company calls a bold structure that reflects its commitment to accelerating expansion across the US and Canada. The growth responsibilities for this expansion will be shared across the two roles rather than one executive, which the company believes will allow it to scale faster while strengthening field support.

Boles brings almost two decades of direct selling experience and is known for converting underperforming regions into thriving markets. Previously, she led international launches and large-scale transformations for organizations.

Dodd brings two decades of experience guiding companies through “explosive growth,” meaning 200% year-over-year improvements. Previously, she worked with billion-dollar corporations and startups where she worked to develop leaders, elevated culture and accelerated results.

“This moment represents more than just a leadership appointment—it’s a declaration of where we’re headed as a company,” said Mauricio Domenzain, Immunotec CEO. “The US is a critical market for us, and by investing in dynamic leaders and scalable systems, we’re ensuring Immunotec’s science and opportunity will continue to change lives for generations to come.”